Clinical trial · Interventional
Inferior Epigastric Lymp Node (IELN) Basin as a Possible Systemic Metastatic Pathway of Ovarian Peritoneal Metastases
NCT06237582CI-TRIAL-00120927OvEpiLyPathcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The IELN basin could represent a primary LN relay for systemic metastatic dissemination in patients with OPM. This newly described lymphatic pathway of metastatic dissemination of OPM may be involved in certain presentations of peritoneal dissemination. The presence of invaded IELN may represent a new biomarker predictive of the pattern of progression of OPM and a related risk for systemic dissemination.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinomatosis, Peritoneal | Peritoneal Carcinomatosis | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| epigastric lymph node biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- patients
- description
- patients planned for complete cytoreductive surgery Only one arm in the study: all patients operated for complete cytoreductive surgery and who signed informed consent form
- interventionNames
- Procedure: epigastric lymph node biopsy
Primary outcomes (1)
- measure
- Incidence of IELN invasion by ovarian cancer
- timeFrame
- 2 years
- description
- Number of invaded lymph nodes in the inferior epigastric lymp node basin to evaluate the incidence of IELN invasion by ovarian cancer
Secondary outcomes (2)
- measure
- proportion of invaded IELN lymph nodes
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who will undergo complete cytoreductive surgery for peritoneal metastases from ovarian origin Exclusion Criteria: * Minor patients * Patients unable to give written informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.